SetPoint Medical secures $140M to fund neuromodulation for arthritis

SetPoint Medical secures $140M to fund neuromodulation for arthritis

Abbott and Boston Scientific are among the investors in SetPoint, whose neurostimulation device gained FDA approval last month.

SetPoint Medical Raises $140M to Support Commercialization of Rheumatoid Arthritis Therapy

What You Should Know:  – SetPoint Medical, a company focused on developing innovative therapies for chronic autoimmune diseases secures $140M in private financing. This includes the final $25M tranche of its Series C funding and a substantial $115M Series D round co-led by Elevage Medical Technologies and Ally Bridge Group.  – The funding will fuel the commercialization of the SetPoint System, a groundbreaking neuroimmune modulation therapy for …